Increase of [ 18F]FLT tumor uptake in vivo mediated by FdUrd: Toward improving cell proliferation positron emission tomography

Molecular Imaging and Biology

Volumn 13, Issue 2, 2011, Pages 321-331

  Viertl, David ^a   Delaloye, Angelika Bischof ^a   Lanz, Bernard ^b   Poitry Yamate, Carole ^b   Gruetter, Rolf ^b   Mlynarik, Vladimir ^b   Ametamey, Simon M ^c   Ross, Tobias L ^c   Lehr, Hans Anton ^a   André, Pierre Alain ^a   Perillo Adamer, Florence ^a   Kosinski, Marek ^a   Dupertuis, Yves M ^d   Buchegger, Franz ^a,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

18F FLT; Cell proliferation; FdUrd; PET; Thymidine synthesis

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLOXURIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOMA; MOLECULAR DYNAMICS; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FLOW CYTOMETRY; FLOXURIDINE; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 79955930275     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0368-z     Document Type: Article

References (29)

1. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S-80S
2. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263:8350-8358
3. Been LB, Elsinga PH, deVries J et al (2006) Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l- thymidine ((18)F-FLT) - a pilot study. Eur J Surg Oncol 32:39-43
4. Yamamoto Y, Nishiyama Y, Ishikawa S et al (2007) Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34:1610-1616 (Pubitemid 47476919)
5. Buck AK, Bommer M, Juweid ME et al (2008) First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine. J Nucl Med 49:1756-1762
6. Vesselle H, Grierson J, Muzi M et al (2002) In vivo validation of 3′ deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315-3323
7. Kameyama R, Yamamoto Y, Izuishi K et al (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36:382-388
8. Troost EG, Vogel WV, Merkx MA et al (2007) 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48:726-735 (Pubitemid 47604972)
9. Solit DB, Santos E, Pratilas CA et al (2007) 3′-Deoxy-3′- [18F] fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 67:11463-11469 (Pubitemid 350248575)
10. Everitt S, Hicks RJ, Ball D et al (2009) Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial (18)F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 75:1098-1104
11. Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945-952 (Pubitemid 43733508)
12. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347 (Pubitemid 47312585)
13. Herrmann K, Wieder HA, Buck AK et al (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13:3552-3558 (Pubitemid 46955115)
14. Kostakoglu L, Agress H Jr, Goldsmith SJ (2003) Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23:315-340, quiz 533
15. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414-419 (Pubitemid 23075381)
16. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507 (Pubitemid 43200300)
17. Tian J, Yang X, Yu L et al (2008) A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 49:186-194 (Pubitemid 351225655)
18. Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ (1969) Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 24:223-228
19. Kim DW, Ahn DS, Oh YH et al (2006) A new class of SN2 reactions catalyzed by protic solvents: facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 128:16394-16397 (Pubitemid 44936636)
20. Foulon CF, Adelstein SJ, Kassis AI (1996) Kit formulation for the preparation of radiolabeled iododeoxyuridine by demetallation. J Nucl Med 37:1S-3S
21. Dupertuis YM, Vazquez M, Mach JP et al (2001) Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res 61:7971-7977 (Pubitemid 33049390)
22. Marques JP, Maddage R, Mlynarik V, Gruetter R (2009) On the origin of the MR image phase contrast: an in vivo MR microscopy study of the rat brain at 14.1 T. Neuroimage 46:345-352
23. Yamamoto Y, Nishiyama Y, Ishikawa S et al (2008) 3′-Deoxy-3′- 18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. J Comput Assist Tomogr 32:432-437
24. Barwick T, Bencherif B, Mountz JM, Avril N (2009) Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 30:908-917
25. Direcks WG, Berndsen SC, Proost N et al (2008) [18F]FDG and [18F] FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 99:481-487
26. Dupertuis YM, Xiao WH, De Tribolet N et al (2002) Unlabelled iododeoxyuridine increases the rate of uptake of [125I]iododeoxyuridine in human xenografted glioblastomas. Eur J Nucl Med Mol Imaging 29:499-505
27. Dittmann H, Dohmen BM, Kehlbach R et al (2002) Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29:1462-1469 (Pubitemid 35232048)
28. Leichman L, Silberman H, Leichman CG et al (1992) Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 10:1933-1942 (Pubitemid 23064206)
29. Sullivan RD, Miller E (1965) The clinical effects of prolonged intravenous infusion of 5-fluoro-2′-deoxyuridine. Cancer Res 25:1025-1033